Short Interest in BioCardia, Inc. (NASDAQ:BCDA) Decreases By 5.4%

BioCardia, Inc. (NASDAQ:BCDA) saw a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 103,600 shares, a decline of 5.4% from the November 15th total of 109,500 shares. Based on an average daily volume of 99,900 shares, the days-to-cover ratio is currently 1.0 days. Currently, 2.9% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of BioCardia in a research note on Thursday, November 14th.

BioCardia Stock Up 0.5 %

Shares of BCDA stock opened at $2.09 on Tuesday. BioCardia has a twelve month low of $1.84 and a twelve month high of $10.79. The stock’s fifty day simple moving average is $2.35 and its 200 day simple moving average is $2.79. The firm has a market capitalization of $9.58 million, a P/E ratio of -0.50 and a beta of 1.25.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.